|
" Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents : "
edited by Joel Morganroth, E. Neil Moore.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
716409
|
| Doc. No
|
:
|
b536092
|
| Main Entry
|
:
|
edited by Joel Morganroth, E. Neil Moore.
|
| Title & Author
|
:
|
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents : : Proceedings of the Ninth Annual Symposium on New Drugs Devices, October 27 28, 1988\ edited by Joel Morganroth, E. Neil Moore.
|
| Publication Statement
|
:
|
Boston, MA: Springer US, 1989
|
| Series Statement
|
:
|
Developments in cardiovascular medicine, 100.
|
| Page. NO
|
:
|
(316 pages).
|
| ISBN
|
:
|
1461316057
|
|
|
:
|
: 9781461316053
|
| Contents
|
:
|
I. Thrombolytic Agents: Clinical Trials ISSUES --;1. Measurement of infarct size: effect of reperfusion with arterial blood --;2. Pitfalls in the design and evaluation of clinical trials of intravenously administered cardiovascular drugs --;3. The relative benefit and risks of intravenous streptokinase and tissue plasminogen activator in acute myocardial infarction --;4. New agents and new insights for thrombolytic therapy in acute myocardial infarction: focus on anistreplase, urokinase, and prourokinase --;5. Myocardial reperfusion: Role of adjunctive agents to improve reperfusion and prevent reperfusion injury --;Panel Discussion --;II. Thrombolytic Agents: Adjunctive Issues --;6. Interactions between thrombolysis and sudden cardiac death --;7. What are the overall strategies for post-thrombolytic care that include use of angioplasty? --;8. Thrombolytic agents: biologic properties and issues regarding products derived by recombinant DNA technology --;Panel Discussion --;III. Risk vs. Benefit for Antiarrhythmic Drugs --;9. What do new anti-arrhythmic agents have to show to establish a favorable risk versus benefit ratio? --;10. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? --;clinical viewpoint --;11. Is it practical to develop a class III antiarrhythmic agent? --;Panel Discussion --;IV. Hypolipidemic Agents: Clinical & Regulatory Issues --;12. What are the recommendations to the medical community to institute hypolipidemic therapy? --;13. What are the comparative risks versus benefits for bile acid sequestrants, HMG CO-A reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives? --;14. What levels of cholesterol should be studied and what should be the study designs? --;15. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents? --;16. How and when should long-term safety data be obtained for hypolipidemic agents? --;17. What is required to gain approval of lipid altering drugs? --;Panel Discussion --;Participant List.
|
| Abstract
|
:
|
Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988
|
| Subject
|
:
|
Cardiology.
|
| Subject
|
:
|
Health Biological Sciences.
|
| Subject
|
:
|
Medicine.
|
| LC Classification
|
:
|
RC685.C6E358 1989
|
| Added Entry
|
:
|
E Neil Moore
|
|
|
:
|
Joel Morganroth
|
| Parallel Title
|
:
|
Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988
|
| |